Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for EFAVIRENZ
- A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy
- An Open-label, Single Sequence, 2-period Crossover DDI Study of Omaveloxolone in Healthy Subjects
- Interaction of CYP2B6 Genotype and Efavirenz Methadone and Tizanidine PK
- A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
- Adipose Tissue After Switch to Doravirine
- Letermovir in ART-treated HIV-infected Persons
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
- BFTAF Elderly Switch Study
- Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy
- A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
- Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)
- A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
- A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
- The Role of Home Packs of HIV PEPSE in High Risk Individuals
- Flucloxacillin as an Inducer of CYP-enzymes
- Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients
- Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
- Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals
- Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)
- Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
- Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients
- HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
- Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients
- Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
- Efficacy of Efavirenz 400mg vs. 600mg Combined With Lamivudine and Tenofovir in Treatment Naive HIV Infection
- A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
- DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV
- ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance
- A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.
- Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
- Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients
- Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)
- ANRS 12372 MODERATO Study
- Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial
- Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects
- Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
- Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
- Bioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid Dispersions
- Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
- Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
- ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ
- Tuberculosis Clinical Trials Consortium Study 35
- Efavirenz for Patients With Alzheimer's Disease
- Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan
- Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine
- B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
- Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1
- Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
- Extended Duration Artemether-lumefantrine Treatment for Malaria in Children
- Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
- Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
- Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir
- Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
- Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression
- Dolutegravir in Pregnant HIV Mothers and Their Neonates
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio
- ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
- Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
- Rilpivirine in Virologically Suppressed Adolescents
- Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
- Optimization of Antiretroviral Therapy
- Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
- Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz
- Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
- Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings
- Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women
- Dose Optimisation of Stavudine for the Treatment of HIV Infection
- Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
- ART Drug Dosage Adjustment in HIV-infected Population
- PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers
- Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS
- Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
- Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet
- Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
- SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
- SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women
- Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
- Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
- Risk of CV Events With EFV vs. EFV-free Regimens
- Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients
- PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
- PK TDF in Thai HIV-infected Children
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
- CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
- Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation
- The Lighthouse Tenofovir Cohort Study
- Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppresse
- HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
- Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning
- Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity
- Sleep and Cognition After Atripla to Stribild Switch
- Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
- A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation
- Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers
- Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects
- Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
- Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study
- Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
- Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers
- Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
- Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects
- A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
- Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women
- A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy
- Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
- Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
- Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
- Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection
- Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
- Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
- Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density
- LAAM-HAART PET Imaging
- Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
- Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone
- Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
- Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
- Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection
- EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
- Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)
- Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy
- Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients
- Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB
- A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy
- Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
- Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
- Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection
- A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen
- A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
- Efavirenz Comparative Bioavailability
- A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
- Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
- Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
- Efavirenz and Ritonavir on Human Brain P-Glycoprotein
- Abacavir and Lamivudine PK in Children
- Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
- BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection
- Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
- A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
- Evaluation of the Bioequivalence of a Combined Formulated Tablet
- Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
- Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients
- Atazanavir/r + Lamivudine Dual Therapy
- A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers
- Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
- Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
- Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
- Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs
- An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
- Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
- The Neurocognitive Sub-study of Encore1
- Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
- Telaprevir Open-Label Study in Co-Infected Patients
- Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
- Antiretroviral Drug Interaction Study in Volunteers With HIV
- A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
- Drug Exposure Registry for GSK2248761, an Investigational NNRTI
- The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
- A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)
- Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
- High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
- Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression
- REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
- Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers
- Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa
- Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
- Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.
- Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection
- Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
- Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiret
- Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals
- Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
- The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
- Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
- A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
- A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
- Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
- A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022
- TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir
- Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
- Depot Contraception With and Without Lopinavir/Ritonavir
- Safety Study of Raltegravir in HIV/HCV Co-infected Patients
- Atripla to Raltegravir Switch Study for CNS Toxicity
- Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
- PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial
- PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen
- Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes
- Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
- Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz
- Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
- Treatment Options for Protease Inhibitor-exposed Children
- Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
- Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers
- PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
- Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users
- Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
- GSK1349572 Drug Interaction Study With Efavirenz
- Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- Sustiva Levels With Use of a Gel Capsule
- Cryptococcal Optimal ART Timing Trial
- Pre-Exposure Prophylaxis Using TMC278LA
- Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy
- Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens
- Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity
- Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status
- Appropriate Timing of HAART in Co-infected HIV/TB Patients
- Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.
- Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
- Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
- Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients
- Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
- Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients
- Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects
- CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
- Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
- Efavirenz in Treating Patients With Metastatic Prostate Cancer
- Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
- A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
- Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
- Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz
- Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial
- Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
- A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
- Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
- Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
- Disulfiram Interactions With HIV Medications: Clinical Implications
- A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
- Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
- Raltegravir Activity In Lymphoid Tissues
- The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers
- Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
- VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
- A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
- Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
- Comparative Study of Three NNRTI-Sparing HAART Regimens
- Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CY
- Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
- A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
- Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz
- Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125
- Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
- An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
- NNRTI/PI Toxicity Switch to Darunavir Study
- Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism
- Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients
- TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.
- Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
- Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
- Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
- VENICE Study Nevirapine Full Dose/Dose Escalation
- Durability of Nevirapine-Based Antiretroviral Regimen
- Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc
- Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations
- Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
- Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy
- Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
- Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients
- ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
- ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
- Relationship Between HIV-1 Subtype and ARV Response
- Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage
- KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
- Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
- TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
- Pediatric Expanded Access Program-Oral Solution (0831-908)
- TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
- Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg
- Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
- TMC 125 Blood Levels Study
- HIV Antiretroviral Drugs and Metabolism
- A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV
- Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
- Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)
- Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin
- A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication
- A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects
- Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis
- Mechanisms of Lipodystrophy in HIV-Infected Pateints
- Anti-Retrovirals for Kaposi's Sarcoma
- HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV
- Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis
- Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV
- Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya
- Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
- FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment
- The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin
- Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia
- Drug Interaction - Oral Contraceptive
- Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.
- A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
- Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients
- Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
- Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
- Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
- A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
- Antiretroviral Therapy for Advanced HIV Disease in South Africa
- ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
- Structured Treatment Interruptions in Chronic HIV Infection
- SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection
- Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients
- Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
- Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
- Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)
- Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients
- Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment
- A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort
- Drug Interaction Study Between Antimalarial and Anti-HIV Medications
- Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children
- Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV
- Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities
- When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
- Combination of Efavirenz and Truvada - COMET Study
- Once Daily 3TC, Efavirenz and ddI for HIV Infection
- Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
- Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults
- PI Vs. NNRTI Based Therapy for HIV Advanced Disease
- An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
- An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada
- Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
- Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression
- Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
- Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)
- Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)
- Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)
- Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
- A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
- 2NN & CHARM Long-Term Follow-up Study
- Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
- Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
- Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)
- A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
- Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti
- Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
- DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
- Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)
- DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
- Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
- Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
- A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
- Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China
- Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
- Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal
- A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
- Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
- Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings
- Three Month Course of Anti-HIV Medications for People Recently Infected With HIV
- Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
- Strategies for Delivering Anti-HIV Therapy in South Africa
- Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
- A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
- Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
- Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
- Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A 14-Day Study of Racivir When Used in Combination in HIV-Infected Males
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children
- Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
- Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
- Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children
- Increasing HAART-Induced Immune Restoration With Cyclosporine
- Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
- Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
- TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
- Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
- Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
- Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
- The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
- Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
- Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women
- Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
- A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
- Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
- Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Capravirine to Treat Children With HIV Infection
- A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
- A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
- Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
- Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
- Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
- Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
- Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
- Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
- Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
- A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
- ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
- A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
- A Study to Compare Two Anti-HIV Drug Combinations
- Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
- A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
- A Study of Indinavir Taken With or Without DMP 266
- The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz
- A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
- A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
- Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients
- A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- A Study of Efavirenz in Combination With Stavudine and Didanosine
- Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
- The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors
- Combination Drug Treatment of Pediatric HIV Infection
- Drug Interactions Among Anti-HIV Agents
- Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
- A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
- Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
- The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients
- A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
- A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
- A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
- A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks
- A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
- Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen
- Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
- Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
Clinical trials list
click for details